Cantuzumab ravtansine

• UNSPSC Description:

  Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cantuzumab-ravtansine.html

• Purity:

  98.71

• Solubility:

  10 mM in DMSO

• Smiles:

  [Cantuzumab ravtansine]

• Molecular Weight:

  150000 (average)

• References & Citations:

  [1]Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335.|[2]Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement): A127.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C, protect from light

• Clinical Information:

  Phase 2

• CAS Number:

  868747-45-9